Alembic Pharmaceuticals Limited — Updates, 06-05-2025: Press Release

Alembic Pharmaceuticals has announced a board meeting to review the financial results for the quarter and half-year. Q4 revenue rose 17% to Rs. 1770 Cr, driven by US Generics (+20%) and Ex-US Generics (+43%). India Branded Business grew 8%, led by specialties like gynecology and dermatology, while Animal Health increased 19%. EBITDA increased 9% to Rs. 286 Cr and PBT rose 5% to Rs. 192 Cr. New product launches and ANDA approvals continue to bolster growth across key markets.